Department of Radiology

Publications

2019

Glodzik L, Rusinek H, Tsui W, Pirraglia E, Kim H-, Deshpande A, et al. Different Relationship Between Systolic Blood Pressure and Cerebral Perfusion in Subjects With and Without Hypertension. Hypertension. 2019;73(1):197-205.

Qiu W, Li D, Jin X, Liu F, Nguyen TD, Prince MR, et al. Sliding motion compensated low-rank plus sparse (SMC-LS) reconstruction for high spatiotemporal free-breathing liver 4D DCE-MRI. Magn Reson Imaging. 2019;58:56-66.

Zhang S, Liu Z, Nguyen TD, Yao Y, Gillen KM, Spincemaille P, et al. Clinical feasibility of brain quantitative susceptibility mapping. Magn Reson Imaging. 2019;60:44-51.

Parker DB, Razlighi QR. The Benefit of Slice Timing Correction in Common fMRI Preprocessing Pipelines. Front Neurosci. 2019;13:821.

Jafari R, Sheth S, Spincemaille P, Nguyen TD, Prince MR, Wen Y, et al. Rapid automated liver quantitative susceptibility mapping. J Magn Reson Imaging. 2019;50(3):725-732.

Miyata M, Kakeda S, Toyoshima Y, Ide S, Okada K, Adachi H, et al. Potential usefulness of signal intensity of cerebral gyri on quantitative susceptibility mapping for discriminating corticobasal degeneration from progressive supranuclear palsy and Parkinson's disease. Neuroradiology. 2019;61(11):1251-1259.

Zhang J, Kim SG. Estimation of cellular-interstitial water exchange in dynamic contrast enhanced MRI using two flip angles. NMR Biomed. 2019;32(11):e4135.

Reyes-Madrigal F, León-Ortiz P, Mao X, Mora-Durán R, Shungu DC, de la Fuente-Sandoval C. Striatal Glutathione in First-episode Psychosis Patients Measured In Vivo with Proton Magnetic Resonance Spectroscopy. Arch Med Res. 2019;50(4):207-213.

Seligman L, Kovanlikaya I, Pisapia DJ, Naeger DM, Magge R, Fine HA, et al. Integrated PET-MRI for Glioma Surveillance: Perfusion-Metabolism Discordance Rate and Association With Molecular Profiling. AJR Am J Roentgenol. 2019;212(4):883-891.

Pandit-Taskar N, Zanzonico PB, Kramer K, Grkovski M, Fung EK, Shi W, et al. Biodistribution and Dosimetry of Intraventricularly Administered I-Omburtamab in Patients with Metastatic Leptomeningeal Tumors. J Nucl Med. 2019;60(12):1794-1801.